GlassScriptPhysician profile
Kevin G Barber
NPI 1861461196
$5,816.29
in general payments reported to CMS, 2019-2025
32 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $379 · 2021: $683 · 2022: $905 · 2023: $659 · 2024: $1,420 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138 · Education: $80.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.91 |
| Education | $80.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $886.86 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $598.99 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $545.69 | 2022-2025 | |
| Amgen INC. | $475.17 | 2020-2025 | Krystexxa, Repatha, Repatha |
| Fresenius USA Marketing, INC. | $453.84 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $449.79 | 2019-2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $385.33 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $235.70 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.07 | 2022-2025 | |
| Exeltis, USA INC. | $175.96 | 2021-2025 | Slynd |
| Mallinckrodt Hospital Products INC. | $174.77 | 2020-2025 | Terlivaz, Acthar |
| Ani Pharmaceuticals, INC. | $162.43 | 2024-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $156.59 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $125.46 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $111.94 | 2023-2025 | Benlysta, Jesduvroq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $100.00 | 2024 | Argyle |
| Aurinia Pharma U.S., INC. | $74.54 | 2023-2024 | Lupkynis |
| Esperion Therapeutics, INC. | $64.06 | 2024 | Nexletol |
| Boston Scientific Corporation | $61.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $55.53 | 2019-2022 | |
| Daiichi Sankyo INC. | $43.14 | 2021-2022 | |
| Ardelyx, INC. | $39.93 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $38.91 | 2025 | Empaveli |
| Vantive US Healthcare LLC | $32.73 | 2025 | Renal - Pd |
| Baxter Healthcare | $26.66 | 2024 | Renal - Pd |
| Inari Medical, INC. | $19.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cormedix INC. | $18.51 | 2025 | Defencath |
| Covidien LP | $18.45 | 2019 | |
| Exact Sciences Corporation | $17.15 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $14.83 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.54 | 2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.